Who Owns Twist Bioscience Company?

Twist Bioscience Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Twist Bioscience?

Understanding Twist Bioscience's ownership is key to grasping its strategic direction and accountability. A significant move was the spin-out of its DNA data storage technology into Atlas Data Storage in May 2025, allowing both entities to focus on their core missions.

Twist Bioscience, founded in 2013, is a public biotechnology company focused on industrializing biology through its DNA synthesis platform. This technology enables high-throughput and cost-effective production of synthetic DNA.

As of July 23, 2025, Twist Bioscience has a market capitalization of $2.16 billion. The company reported record revenue of $92.8 million for Q2 fiscal 2025, with trailing 12-month revenue reaching $348 million as of March 31, 2025. Its synthetic DNA products are crucial across pharmaceuticals, diagnostics, agriculture, and technology, supporting advancements like antibody development and the innovative Twist Bioscience Porter's Five Forces Analysis.

Twist Bioscience was established in 2013 by a trio of visionary founders: Emily Leproust, Bill Banyai, and Bill Peck. Emily Leproust, who also leads the company as CEO, is recognized as an early innovator in high-throughput DNA synthesis, holding a Ph.D. in organic chemistry. Bill Banyai and Bill Peck were instrumental as co-founders, contributing to the company's initial drive to revolutionize synthetic DNA manufacturing.

Founding Team

Emily Leproust, Bill Banyai, and Bill Peck founded the company in 2013. Leproust serves as CEO and is a pioneer in DNA synthesis.

Core Technology

The company's initial focus was on a silicon-based platform for synthetic DNA manufacturing. This technology aimed to significantly increase throughput and reduce costs.

Early Funding Rounds

Significant investment was secured through multiple early funding rounds. These rounds demonstrated strong investor confidence in the company's disruptive potential.

Series A Funding

In February 2014, the company raised $9.1 million in its Series A funding. ARCH Venture Partners and Paladin Capital Group led this initial investment.

Series B and C Rounds

A $26 million Series B round in May 2014 and a $37 million Series C round in June 2015 followed. These rounds saw participation from notable entities like DARPA and Illumina.

Series D and Debt Facility

By January 2016, the company had raised $61 million in a Series D round, complemented by a $20 million debt facility. This brought the total funding to $133 million at that time.

The early ownership structure of the company was heavily influenced by its founders and the venture capital firms that provided crucial early-stage funding. Key investors like ARCH Venture Partners and Illumina demonstrated a sustained commitment, participating in multiple funding rounds. This consistent backing underscored their belief in the founding team's expertise and the transformative nature of the company's DNA synthesis technology, as detailed in the Brief History of Twist Bioscience.

Key Early Investors

Several prominent investors played a significant role in the company's early financial backing. Their continued participation highlighted strong confidence in the company's trajectory.

• ARCH Venture Partners
• Paladin Capital Group
• DARPA
• Yuri Milner
• Foresite Capital
• Fidelity Management & Research
• Illumina

Twist Bioscience SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Twist Bioscience's transition to a publicly traded entity on Nasdaq under the ticker TWST marked a significant shift in its ownership structure. The company has successfully secured substantial funding, totaling $321 million across 11 funding rounds, which has facilitated its growth and expansion in the synthetic biology market.

As of July 18, 2025, the ownership landscape of Twist Bioscience is dominated by institutional investors, who collectively hold a significant portion of the company's shares. These entities, comprising 569 distinct owners who have filed with the SEC, manage a total of 89,979,377 shares, indicating a strong belief in the company's long-term prospects. Insiders hold a smaller but notable stake of 2.55%, while public companies and individual investors account for the remaining 41.19%.

Key Institutional Investors in Twist Bioscience

Several prominent institutional investors have made substantial commitments to Twist Bioscience, underscoring their confidence in the company's innovative approach to synthetic biology.

• ARK Investment Management LLC is a leading shareholder with 6,241,595 shares as of March 31, 2025.
• Vanguard Group Inc. holds 5,867,459 shares, reflecting broad market participation.
• Artisan Partners Limited Partnership has invested in 5,851,374 shares.
• BlackRock, Inc. possesses 5,632,915 shares, demonstrating significant institutional backing.
• William Blair Investment Management, Llc holds 3,806,867 shares.
• Other notable investors include Invesco Ltd., State Street Corp, UBS Asset Management Americas Inc., and Sumitomo Mitsui Trust Holdings, Inc.

The significant stake held by ARK Investment Management LLC in the Genomic Revolution ETF (ARKG), representing 6.88% of its portfolio as of July 9, 2025, highlights the company's strategic importance within the genomics sector. Understanding these major stakeholders is crucial for grasping the dynamics of Twist Bioscience ownership and its potential future direction, as detailed in the Marketing Strategy of Twist Bioscience.

Twist Bioscience PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The leadership at Twist Bioscience is anchored by its co-founder and CEO, Emily Leproust, who also holds a position on the board. Other significant figures include Patrick Finn, President and Chief Operating Officer, and Adam Laponis, Chief Financial Officer. The continued involvement of co-founder Bill Banyai as Senior VP of Advanced Development, GM of Data Storage, and Director underscores the foundational presence within the company's governance.

Regarding voting power, while specific details on dual-class shares or special voting rights are not publicly detailed, the substantial institutional ownership indicates significant influence for major shareholders. Entities like Vanguard Fiduciary Trust Co., holding 9.836%, and Artisan Partners Holdings LP, with 9.809%, possess considerable voting power, assuming a standard one-share-one-vote structure. These large stakes mean that these institutional investors, through their board representation or direct engagement, likely play a crucial role in the company's decision-making processes. Investors can track insider and major shareholder activities through the company's SEC filings, such as Form 4 statements and Form 144 notices.

Understanding Twist Bioscience's Shareholder Landscape

The ownership structure of Twist Bioscience is heavily influenced by its institutional investors. These entities, due to their significant shareholdings, wield considerable voting power.

• Vanguard Fiduciary Trust Co. owns 9.836% of the company's shares.
• Artisan Partners Holdings LP holds 9.809% of the company's shares.
• The presence of founders on the board signifies ongoing strategic involvement.
• Independent directors ensure diverse perspectives in board decisions.
• Understanding Target Market of Twist Bioscience is key to appreciating its investor base.

Twist Bioscience Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent strategic maneuvers have reshaped the ownership landscape for Twist Bioscience, particularly with the spin-off of its DNA data storage division. This move, coupled with consistent revenue growth and ongoing efforts toward profitability, highlights a dynamic period for the company's stakeholders.

Twist Bioscience has demonstrated significant revenue expansion, achieving a record $92.8 million in Q2 fiscal 2025, a 23% increase year-over-year. The company projects Q3 fiscal 2025 revenue to be between $94 million and $97 million. While net losses have narrowed to -$39.33 million in Q2 fiscal 2025 from -$45.49 million in the prior year's quarter, the company is targeting adjusted EBITDA breakeven by the close of fiscal 2026. This financial trajectory is occurring within a sector experiencing a notable rise in institutional ownership, a trend that also reflects in Twist Bioscience's shareholder base.

Focus on Core Business

The spin-out of its DNA data storage unit allows Twist Bioscience to concentrate on its primary life sciences operations. This strategic alignment is expected to enhance efficiency and innovation in its core offerings.

Investor Confidence and Growth

Consistent revenue growth, exemplified by the Q2 fiscal 2025 record, signals increasing market traction. The company's pursuit of profitability by fiscal 2026 is a key focus for its investors.

Institutional Investment Trends

The synthetic biology sector is seeing a surge in institutional backing, and Twist Bioscience is a beneficiary of this trend. A significant portion of its stock is held by institutional investors, reflecting broad market interest.

Shareholder Structure Dynamics

Recent equity grants to new employees can influence the overall ownership structure. Understanding these grants is key to tracking potential shifts in share distribution and employee stakes.

Twist Bioscience Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔